Treatment sequencing patterns and healthcare resource utilization in patients with Crohn’s disease initiating biologics: a 3-year retrospective claims-based analysis
This analysis reveals variability in biologic treatment patterns. Most biologic-naïve patients start with anti-TNFs, even though other therapies show numerically higher persistence than anti-TNFs, highlighting the need for effective treatment sequencing and monitoring. Rising healthcare costs emphasize strategic decisions for effective biologics and efficient resource allocation in real-world settings.
Authors
- Wanjiku Kariuki
- Rifat Tuly (ORCID: https://orcid.org/0000-0002-8437-6034)
- Aisha Vadhariya (ORCID: https://orcid.org/0000-0002-1811-5370)
- Deborah A. Fisher (ORCID: https://orcid.org/0000-0002-8886-3382)
- Amar S. Naik
- Navneet Upadhyay (ORCID: https://orcid.org/0000-0003-3776-9596)
- Magdaliz Gorritz (ORCID: https://orcid.org/0000-0001-6806-3188)
- Nicholas Bires
- Michael Hüll
Institutions
- Eli Lilly (United States) (US)
- IQVIA (United Kingdom) (GB)
- Des Plaines Public Library (US)
- IQVIA (United States) (US)
- Institut de Recherche en Santé Digestive (FR)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/03007995.2025.2581397
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00